author-photo

Sarah Runswick

AstraZeneca

24

Papers

2029

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (187)
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Abstract CT038: OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P5-21-13: Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Abstract P5-21-12: Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (1253)
243PD OlympiAD: further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice.

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines

2012 BMC Medical Genomics
Show All
- Source
- Cite
- Save
Citations (170)